Objective: To observe the clinical effect of Neiyifang (内异方,NYF) in treating endometri-osis and to explore its therapeutic mechanism through observing its influence on plasma β-endorphin β-EP) in different menstr...Objective: To observe the clinical effect of Neiyifang (内异方,NYF) in treating endometri-osis and to explore its therapeutic mechanism through observing its influence on plasma β-endorphin β-EP) in different menstrual stages and levels of prostaglandins (PGs) in menstruation. Methods: NYF was administered to 104 patients with endometriosis one dose daily with 3 successive menstrual cycles as one therapeutic course. Peripheral blood β-EP level in follicular, luteal and menstrual stages, as well as PGF2a, PGE2, thromboxane B2 and 6-keto-PGF1a levels in menstrual stage were detected by RIA, and controlled with those in 15 healthy persons. Results: (1) The total effective rate of NYF was 81. 3% and it showed significant effect in improving patients' clinical symptoms and physical signs; (2) In menstrual stage, the levels of β-EP, 6-keto-PGF1α/ TXB2 were lower(P<0.05) and levels of PGF2a, PGE2, TXB2 and 6-keto-PGF1α, were higher (P<0. 05) in patients than those in control, and the higher the level of PGE2, the severer the menalgia, (3) NYF could increase levels of β-EP, 6-keto-PGF1α, and reduce levels of PGF2α, PGE2 in menstrual stage of patients (all P<0.05). Conclusion: (1) NYF has good clinical effect in treating endometriosis, (2) Patients' symptom of menalgia is closely related with the excessive high levels of PGF2a and PGE2 PGI2/TXA2 ratio disturbance, and excessive low level of β-EP; (3) NYF could significantly decrease the PGE2, PGF1a levels, increase the 6-keto-PGF1a/TXB2 ratio and the level of β-EP, so as to alleviate the menalgia in patients with endometriosis.展开更多
基金This item was supported by National Funds of Natural Sciences(No.30070942)
文摘Objective: To observe the clinical effect of Neiyifang (内异方,NYF) in treating endometri-osis and to explore its therapeutic mechanism through observing its influence on plasma β-endorphin β-EP) in different menstrual stages and levels of prostaglandins (PGs) in menstruation. Methods: NYF was administered to 104 patients with endometriosis one dose daily with 3 successive menstrual cycles as one therapeutic course. Peripheral blood β-EP level in follicular, luteal and menstrual stages, as well as PGF2a, PGE2, thromboxane B2 and 6-keto-PGF1a levels in menstrual stage were detected by RIA, and controlled with those in 15 healthy persons. Results: (1) The total effective rate of NYF was 81. 3% and it showed significant effect in improving patients' clinical symptoms and physical signs; (2) In menstrual stage, the levels of β-EP, 6-keto-PGF1α/ TXB2 were lower(P<0.05) and levels of PGF2a, PGE2, TXB2 and 6-keto-PGF1α, were higher (P<0. 05) in patients than those in control, and the higher the level of PGE2, the severer the menalgia, (3) NYF could increase levels of β-EP, 6-keto-PGF1α, and reduce levels of PGF2α, PGE2 in menstrual stage of patients (all P<0.05). Conclusion: (1) NYF has good clinical effect in treating endometriosis, (2) Patients' symptom of menalgia is closely related with the excessive high levels of PGF2a and PGE2 PGI2/TXA2 ratio disturbance, and excessive low level of β-EP; (3) NYF could significantly decrease the PGE2, PGF1a levels, increase the 6-keto-PGF1a/TXB2 ratio and the level of β-EP, so as to alleviate the menalgia in patients with endometriosis.
